Phase 3 Recruiting Industry
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a…
Sponsor: Pfizer
NCT ID: NCT06758401
Sites in District of Columbia: - Washington DC Veterans Affairs Medical Center — Washington D.C., District of Columbia
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in District of Columbia: - MedStar Georgetown-MedStar Georgetown Transplant Institute University Hospital (MGUH) — Washington D.C., District of Columbia
- MEDSTAR Washington Hospital Center (MedStar Health Research Institute) — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose t…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07195695
Sites in District of Columbia: - George Washington University Cancer Center — Washington D.C., District of Columbia
Phase 3 Recruiting Academic/Other
Primary Objective To compare two smoking cessation interventions among individuals undergoing lung cancer screening. Primary outcomes are: 3-month self-reported abstinence from cigarettes and 6-month self-reported and bioverified abstinenc…
Sponsor: Georgetown University
NCT ID: NCT06290869
Sites in District of Columbia: - Georgetown University Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting Academic/Other
This clinical trial compares efficacy in postoperative pain management in thoracic surgery between erector spinae block versus liposomal bupivacaine injections.
Sponsor: George Washington University
NCT ID: NCT06810375
Sites in District of Columbia: - The George Washington University Hospital — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spr…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06287775
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
Phase 2 Recruiting NIH
This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in th…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04665739
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each othe…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06162221
Sites in District of Columbia: - Georgetown University Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Industry
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combinat…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05498428
Sites in District of Columbia: - Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naï…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT04165070
Sites in District of Columbia: - Georgetown University ( Site 0036) — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the secon…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06810544
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…
Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in District of Columbia: - The George Washington University Cancer Center (site 212) — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
The goal of this clinical trial is to learn about neoadjuvant cemiplimab with histology-specific chemotherapy followed by resection and adjuvant cemiplimab in stage 3 non-small cell lung cancer (NSCLC) with select N3 lymph node involvement…
Sponsor: Georgetown University
NCT ID: NCT06449313
Sites in District of Columbia: - Lombardi Comprehensive Cancer Center, Georgetown University — Washington D.C., District of Columbia
Recruiting Industry
This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this m…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT04165798
Sites in District of Columbia: - Georgetown University ( Site 0036) — Washington D.C., District of Columbia
Phase 4 Recruiting Academic/Other
The aim of this study is to determine if erector spinae injections with bolus infusions with local anesthetic decrease postsurgical pain and opioid consumption in patients undergoing pulmonary resection surgery.
Sponsor: George Washington University
NCT ID: NCT05521789
Sites in District of Columbia: - The George Washington University — Washington D.C., District of Columbia